celecoxib has been researched along with Fibrosis in 9 studies
Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Arthrofibrosis is a common complication following total knee arthroplasty caused by pathologic fibroblast activation and excessive collagen deposition around a synovial joint leading to debilitating loss of motion." | 1.51 | Inhibition of COX-2 Pathway as a Potential Prophylaxis Against Arthrofibrogenesis in a Rabbit Model of Joint Contracture. ( Abdel, MP; Berry, DJ; Bolon, B; Carter, JM; Jay, AG; Jones, CR; Lewallen, EA; Limberg, AK; Morrey, ME; Paradise, CR; Reina, N; Robin, JX; Salib, CG; Sanchez-Sotelo, J; Tibbo, ME; Trousdale, WH; Turner, TW; van Wijnen, AJ, 2019) |
| "Celecoxib was eluted from clinically approved biodegradable collagen membranes over 7 days as measured by UV spectroscopy and high-performance liquid chromatography/mass spectroscopy." | 1.48 | A Drug Eluting Scaffold for the Treatment of Arthrofibrosis. ( Abdel, MP; Berry, DJ; Lewallen, EA; Morrey, ME; Reina, N; Salib, CG; Sanchez-Sotelo, J; Trousdale, WH; van Wijnen, AJ; Viste, A, 2018) |
| "CSA hypertension was associated with renal perivascular fibrosis and divergent changes in immunohistochemical signals of renal arteriolar ETA (increases) and ETB (decreases) receptors." | 1.42 | Celecoxib, but not indomethacin, ameliorates the hypertensive and perivascular fibrotic actions of cyclosporine in rats: role of endothelin signaling. ( Ali, RM; El-Gowelli, HM; El-Mas, MM; Helmy, MW, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Salib, CG | 2 |
| Reina, N | 2 |
| Trousdale, WH | 2 |
| Limberg, AK | 1 |
| Tibbo, ME | 1 |
| Jay, AG | 1 |
| Robin, JX | 1 |
| Turner, TW | 1 |
| Jones, CR | 1 |
| Paradise, CR | 1 |
| Lewallen, EA | 2 |
| Bolon, B | 1 |
| Carter, JM | 1 |
| Berry, DJ | 2 |
| Morrey, ME | 2 |
| Sanchez-Sotelo, J | 2 |
| van Wijnen, AJ | 2 |
| Abdel, MP | 2 |
| Paton, DJW | 1 |
| Kumarasinghe, MP | 1 |
| Viste, A | 1 |
| El-Gowelli, HM | 2 |
| Helmy, MW | 2 |
| Ali, RM | 2 |
| El-Mas, MM | 2 |
| Chen, WD | 1 |
| Yeh, JK | 1 |
| Peng, MT | 1 |
| Shie, SS | 1 |
| Lin, SL | 1 |
| Yang, CH | 1 |
| Chen, TH | 1 |
| Hung, KC | 1 |
| Wang, CC | 1 |
| Hsieh, IC | 1 |
| Wen, MS | 1 |
| Wang, CY | 1 |
| Davids, JS | 1 |
| Carothers, AM | 1 |
| Damas, BC | 1 |
| Bertagnolli, MM | 1 |
| Wang, BH | 1 |
| Bertucci, MC | 1 |
| Ma, JY | 1 |
| Adrahtas, A | 1 |
| Cheung, RY | 1 |
| Krum, H | 1 |
| Zhang, A | 1 |
| Wang, MH | 1 |
| Dong, Z | 1 |
| Yang, T | 1 |
1 review available for celecoxib and Fibrosis
| Article | Year |
|---|---|
NSAID-associated submucosal fibrous nodules of the small intestine revisited.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Fibrosis; Hum | 2020 |
8 other studies available for celecoxib and Fibrosis
| Article | Year |
|---|---|
Inhibition of COX-2 Pathway as a Potential Prophylaxis Against Arthrofibrogenesis in a Rabbit Model of Joint Contracture.
Topics: Animals; Arthroplasty, Replacement, Knee; Biomechanical Phenomena; Celecoxib; Collagen; Contracture; | 2019 |
A Drug Eluting Scaffold for the Treatment of Arthrofibrosis.
Topics: Animals; Celecoxib; Cell Death; Cell Line; Fibrosis; Gene Expression Regulation; Joints; Rabbits; Ti | 2018 |
Celecoxib offsets the negative renal influences of cyclosporine via modulation of the TGF-β1/IL-2/COX-2/endothelin ET(B) receptor cascade.
Topics: Animals; Celecoxib; Creatinine; Cyclooxygenase 2; Cyclosporine; Fibrosis; Immunosuppressive Agents; | 2014 |
Celecoxib, but not indomethacin, ameliorates the hypertensive and perivascular fibrotic actions of cyclosporine in rats: role of endothelin signaling.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclosporine; Cytoprote | 2015 |
Circadian CLOCK Mediates Activation of Transforming Growth Factor-β Signaling and Renal Fibrosis through Cyclooxygenase 2.
Topics: Animals; Celecoxib; Circadian Clocks; CLOCK Proteins; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; | 2015 |
Chronic cyclooxygenase-2 inhibition promotes myofibroblast-associated intestinal fibrosis.
Topics: Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Extracellular Matrix; Female; Fib | 2010 |
Celecoxib, but not rofecoxib or naproxen, attenuates cardiac hypertrophy and fibrosis induced in vitro by angiotensin and aldosterone.
Topics: Aldosterone; Angiotensin II; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Car | 2010 |
Prostaglandin E2 is a potent inhibitor of epithelial-to-mesenchymal transition: interaction with hepatocyte growth factor.
Topics: Actins; Animals; Cadherins; Celecoxib; Cell Line; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinop | 2006 |